BridgeBio Pharma (BBIO) Competitors

BioNTech (NASDAQ:BNTX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment, community ranking and valuation.

Does the MarketBeat Community believe in BNTX or BBIO?

BridgeBio Pharma received 31 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 72.47% of users gave BridgeBio Pharma an outperform vote while only 47.44% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
BioNTech	Outperform Votes 148 47.44%	Underperform Votes 164 52.56%
BridgeBio Pharma	Outperform Votes 179 72.47%	Underperform Votes 68 27.53%

Do institutionals & insiders have more ownership in BNTX or BBIO?

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 18.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Is BNTX or BBIO more profitable?

BioNTech has a net margin of -15.16% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-15.16%	-2.35%	-2.05%
BridgeBio Pharma	-241.44%	N/A	-75.69%

Which has more risk and volatility, BNTX or BBIO?

BioNTech has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.

Which has preferable valuation & earnings, BNTX or BBIO?

BioNTech has higher revenue and earnings than BridgeBio Pharma. BioNTech is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.75B	8.90	$1.01B	-$3.40	-29.92
BridgeBio Pharma	$127.42M	50.24	-$535.76M	-$3.53	-9.55

Does the media prefer BNTX or BBIO?

In the previous week, BioNTech had 2 more articles in the media than BridgeBio Pharma. MarketBeat recorded 19 mentions for BioNTech and 17 mentions for BridgeBio Pharma. BioNTech's average media sentiment score of 1.19 beat BridgeBio Pharma's score of 0.91 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	9 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend BNTX or BBIO?

BioNTech currently has a consensus price target of $142.08, indicating a potential upside of 39.68%. BridgeBio Pharma has a consensus price target of $57.09, indicating a potential upside of 69.36%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.89
BridgeBio Pharma	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92

Summary

BioNTech beats BridgeBio Pharma on 11 of the 19 factors compared between the two stocks.